EGCG targeting efficacy of NF-jB downstream gene products is dictated by the monocytic/macrophagic differentiation status of promyelocytic leukemia cells

Cancer Immunology, Immunotherapy

Volumn 61, Issue 12, 2012, Pages 2321-2331

  Vézina, Amélie ^a,b   Chokor, Rima ^a   Annabi, Borhane ^a  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Blood brain barrier; EGCG; Leukemia; Macrophage differentiation; NF jB

Indexed keywords

CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; GELATINASE B; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LAMININ RECEPTOR; TUMOR MARKER;

ARTICLE; CELL DIFFERENTIATION; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE PRODUCT; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MACROPHAGE; MONOCYTE; NERVOUS SYSTEM INFLAMMATION; NF KAPPA B GENE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

BLOOD-BRAIN BARRIER; CATECHIN; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CYCLOOXYGENASE 2; HL-60 CELLS; HUMANS; I-KAPPA B PROTEINS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MACROPHAGES; MATRIX METALLOPROTEINASE 9; MONOCYTES; NF-KAPPA B; PHOSPHORYLATION; RECEPTORS, LAMININ; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84871022985     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-012-1301-x     Document Type: Article

References (54)

1. Zhu Z, Zhong S, Shen Z (2011) Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol Ther 12(2):95-105
2. Cilloni D, Martinelli G, Messa F et al (2007) Nuclear factor kB as a target for new drug development in myeloid malignancies. Haematologica 92(9):1224-1229
3. Breccia M, Alimena G (2010) NF-jB as a potential therapeutic target in myelodysplastic syndromes and acute myeloid leukemia. Expert Opin Ther Targets 14(11):1157-1176
4. Pepper C, Hewamana S, Brennan P et al (2009) NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. Future Oncol 5(7):1027-1037
5. Fuchs O (2010) Transcription factor NF-jB inhibitors as single therapeutic agents or in combination with classical chemotherapeutic agents for the treatment of hematologic malignancies. Curr Mol Pharmacol 3(3):98-122
6. Larson RA, Daley GQ, Schiffer CA et al (2003) Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia 17(12):2358-2382
7. Park JH, Tallman MS (2011) Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy. Oncology (Williston Park) 25(8):733-741
8. Surh Y (1999) Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat Res 428(1-2):305-327
9. Yang H, Landis-Piwowar KH, Chan T et al (2011) Green tea polyphenols as proteasome inhibitors: Implication in chemoprevention. Curr Cancer Drug Targets 11(3):296-306
10. Khan N, Afaq F, Saleem M et al (2006) Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res 66(5):2500-2505
11. Mereles D, Hunstein W (2011) Epigallocatechin-3-gallate (EGCG) for clinical trials: More pitfalls than promises? Int J Mol Sci 12(9):5592-5603
12. Na HK, Surh YJ (2006) Intracellular signaling network as a prime chemopreventive target of (-)-epigallocatechin gallate. Mol Nutr Food Res 50(2):152-159
13. Demeule M, Michaud-Levesque J, Annabi B et al (2002) Green tea catechins as novel antitumor and antiangiogenic compounds. Curr Med Chem Anticancer Agents 2(4):441-463
14. Thomas DA, Giles FJ, Cortes J et al (2001) Antiangiogenic therapy in leukemia. Acta Haematol 106(4):190-207
15. Moehler TM, Hillengass J, Goldschmidt H et al (2004) Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 10(11):1221-1234
16. Collins SJ, Ruscetti FW, Gallagher RE et al (1978) Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 75(5):2458-2462
17. Huberman E, Callaham MF (1979) Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc Natl Acad Sci USA 76(3):1293-1297
18. Tonetti DA, Henning-Chubb C, Yamanishi DT et al (1994) Protein kinase C-beta is required for macrophage differentiation of human HL-60 leukemia cells. J Biol Chem 269(37):23230-23235
19. Xie B, Laouar A, Huberman E (1998) Autocrine regulation of macrophage differentiation and 92-kDa gelatinase production by tumor necrosis factor-alpha via alpha5 beta1 integrin in HL-60 cells. J Biol Chem 273(19):11583-11588
20. McMillan JI, Weeks R, West JW et al (1996) Pharmacological inhibition of gelatinase B induction and tumor cell invasion. Int J Cancer 67(4):523-531
21. Bingle L, Brown NJ, Lewis CE (2002) The role of tumourassociated macrophages in tumour progression: Implications for new anticancer therapies. J Pathol 196(3):254-265
22. D'Alessandro T, Prasain J, Benton MR et al (2003) Polyphenols, inflammatory response, and cancer prevention: Chlorination of isoflavones by human neutrophils. J Nutr 133(11 Suppl 1): 3773S-3777S
23. Belkaid A, Fortier S, Cao J et al (2007) Necrosis induction in glioblastoma cells reveals a new ''bioswitch'' function for the MT1-MMP/G6PT signaling axis in proMMP-2 activation versus cell death decision. Neoplasia 9(4):332-340
24. Annabi B, Currie JC, Moghrabi A et al (2007) Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCg. Leuk Res 31(9):1277-1284
25. Jin R, Yang G, Li G (2010) Molecular insights and therapeutic targets for blood-brain barrier disruption in ischemic stroke: Critical role of matrix metalloproteinases and tissue-type plasminogen activator. Neurobiol Dis 38(3):376-385
26. Candelario-Jalil E, Taheri S, Yang Y et al (2007) Cyclooxygenase inhibition limits blood-brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 323(2):488-498
27. Umeda D, Yano S, Yamada K et al (2008) Green tea polyphenol epigallocatechin-3-gallate signaling pathway through 67-kDa laminin receptor. J Biol Chem 283(6):3050-3058
28. Arkan MC, Greten FR (2011) IKK-and NF-jB-mediated functions in carcinogenesis. Curr Top Microbiol Immunol 349:159-169
29. Cabrini G, Bezzerri V, Mancini I et al (2010) Targeting transcription factor activity as a strategy to inhibit pro-inflammatory genes involved in cystic fibrosis: Decoy oligonucleotides and lowmolecular weight compounds. Curr Med Chem 17(35):4392-4404
30. Bamborough P, Morse MA, Ray KP (2010) Targeting IKKb for the treatment of rheumatoid arthritis. Drug News Perspect 23(8):483-490
31. Chen S (2011) Natural products triggering biological targets-a review of the anti-inflammatory phytochemicals targeting the arachidonic acid pathway in allergy asthma and rheumatoid arthritis. Curr Drug Targets 12(3):288-301
32. Chen W, Li Z, Bai L et al (2011) NF-kappaB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front Biosci 16:1172-1185
33. Adams H, Obermann EC, Dirnhofer S et al (2011) Targetable molecular pathways in classical Hodgkin's lymphoma. Expert Opin Investig Drugs 20(2):141-151
34. Prasad S, Phromnoi K, Yadav VR et al (2010) Targeting inflammatory pathways by flavonoids for prevention and treatment of cancer. Planta Med 76(11):1044-1063
35. Luqman S, Pezzuto JM (2010) NFkappaB: A promising target for natural products in cancer chemoprevention. Phytother Res 24(7):949-963
36. Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33-40
37. Ono M (2008) Molecular links between tumor angiogenesis and inflammation: Inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 99(8):1501-1506
38. Hazawa M, Takahashi K, Sugata S et al (2011) (-)-Epigallocatechin-3-O- gallate induces nonapoptotic cell death in leukemia cells independent of the 67 kDa laminin receptor. J Nat Prod 74(4):695-700
39. Tergaonkar V (2006) NFkappaB pathway: A good signaling paradigm and therapeutic target. Int J Biochem Cell Biol 38(10): 1647-1653
40. Lakka SS, Gondi CS, Rao JS (2005) Proteases and glioma angiogenesis. Brain Pathol 15(4):327-341
41. Bonoiu A, Mahajan SD, Ye L et al (2009) MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res 1282:142-155
42. Lambert JD, Yang CS (2003) Mechanisms of cancer prevention by tea constituents. J Nutr 133(10):3262S-3267S
43. Demeule M, Brossard M, Pagé M et al (2000) Matrix metalloproteinase inhibition by green tea catechins. Biochim Biophys Acta 1478(1):51-6044.
44. Craggs L, Kalaria RN (2011) Revisiting dietary antioxidants, neurodegeneration and dementia. NeuroReport 22(1):1-3
45. Akool el S, Kleinert H, Hamada FM et al (2003) Nitric oxide increases the decay of matrix metalloproteinase 9 mRNA by inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 23(14):4901-4916
46. Johann AM, Weigert A, Eberhardt W et al (2008) Apoptotic cellderived sphingosine-1-phosphate promotes HuR-dependent cyclooxygenase-2 mRNA stabilization and protein expression. J Immunol 180(2):1239-1248
47. Rusak G, Gutzeit HO, Ludwig-Muller J (2005) Structurally related flavonoids with antioxidative properties differentially affect cell cycle progression and apoptosis of human acute leukemia cells. Nutr Res 25(2):143-155
48. Rice-Evans C, Packer L (eds) (2003) Flavonoids in health and disease, 2nd edn. Marcel Dekker Inc., New York
49. Tahanian E, Sanchez LA, Shiao TC et al (2011) Flavonoids targeting of IjB phosphorylation abrogates carcinogen-induced MMP-9 and COX-2 expression in human brain endothelial cells. Drug Des Devel Ther 5:299-309
50. Williams P, Sorribas A, Howes MJ (2011) Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 28(1):48-77
51. Howes MJ, Perry E (2011) The role of phytochemicals in the treatment and prevention of dementia. Drugs Aging 28(6):439-468
52. Feng SR, Chen ZX, Cen JN et al (2011) Disruption of blood brain-barrier by leukemic cells in central nervous system leukemia. Zhonghua Xue Ye Xue Za Zhi 32(5):289-293
53. Feng S, Cen J, Huang Y et al (2011) Matrix metalloproteinase-2 and-9 secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight junction proteins. PLoS ONE 6(8):e20599
54. Seidel G, Bocker K, Schulte J et al (2011) Pertussis toxin permeabilization enhances the traversal of Escherichia coli K1, macrophages, and monocytes in a cerebral endothelial barrier model in vitro. Int J Med Microbiol 301(3):204-212